University of Hawai‘i at Manoa Homepage

Faculty

Kenneth N. M. Sumida, MD

Kenneth N. M. Sumida, MD
  • Associate Clinical Professor
    Clinical and Translational Research Program
    University of Hawai‘i Cancer Center
  • Assistant Professor
    Department of Medicine;
    Associate Program Director
    Internal Medicine Residency Program
    John A. Burns School of Medicine, University of Hawaii at Manoa
  • Director of Medical Education
    Kuakini Medical Center
  • Private Practice Oncologist
    OnCare Hawai‘i, Inc.

Degrees

  • MD
    John A. Burns School of Medicine
    University of Hawai‘i at Manoa

Research Focus

Dr. Sumida's current activities will include continued participation in the NCI-funded Hawai‘i Minority-Based Community Clinical Oncology Program (MBCCOP) at the University of Hawai‘i Cancer Center. In addition, he will continue as Principal Investigator for the National Surgical Adjuvant Breast and Bowel Program (NSABP) also at the Cancer Center. He has and will continue to serve on various Cancer Center committees including the Clinical Research Advisory Board (CRAB) and various other ad hoc committees.

Selected Publications

  • Assessment of Pain in Older Asian Americans with Cancer. Chung SM, Masaki KH, Somogyi-Zalud E, Sumida KN, Wen A, Blanchette PL. Hawai‘i Med J. 2009 Apr; 68(3):62-5.
  • Long-term Outcome of Radiofrequency Ablation for Unresectable Liver Metastases from Colorectal Cancer: Evaluation of Prognostic Factors and Effectiveness in First- and Second-line Management. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW. Cancer J. 2006 Jul-Aug; 12(4):318-26.
  • Improvement of long-term survival of colorectal cancer in Japanese-Americans of Hawai‘i from 1990 to 2001, Masaki Hata, Kazuhiro Sakamoto; Janine Doneza; Kenneth Sumida; Kiichi Sugimoto; Shun Ishiyama; Makoto Takahashi; Yutaka Kojima; Yuichi Tomiki; Junji Machi, International journal of clinical oncology 2010;15(6):559-64.
  • Parathyroid Hormone Expression in a Patient with Metastatic Nasopharyngeal Rhabdomyosarcoma and Hypercalcemia. Wong K, Tsuda S, Mukai R, Sumida K, Arakaki R. Endocrine. 2005 Jun; 27(1):83-6.
  • Prevalence of Venous Thromboembolism at a Teaching Hospital in Okinawa, Japan. Kishimoto M, Lim HY, Tokuda Y, Narita M, Kitazono H, Ito H, Seto TB, Sumida KN, Gelber RP. Thromb Haemost. 2005 May; 93(5);876-9.

Publication list via PubMed

Active Grants

  • K. Sumida, Principal Investigator
    National Surgical Adjuvant Breast and Bowel Project (NSABP)
    University of Hawai‘i Cancer Center, University of Hawai‘i, Honolulu, Hawai‘i
  • K. Sumida, Sub-Investigator
    A randomized, 3 arm multicentre, phase III study to evaluate the efficacy and the safety of T-DM1combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER-2 positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)
    2011 to Present
  • K. Sumida, Sub-Investigator
    An Open-Label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-
    869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)
    2010 to Present
  • K. Sumida, Sub-Investigator
    Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide
    GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu
    Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2-Node-Positive and High-
    Risk Node-Negative Breast Cancer Patients to Prevent Recurrence
    2010 to Present
  • K. Sumida, Sub-Investigator
    Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
    2010 to Present
  • K. Sumida, Sub-Investigator
    Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 in Standard of Care Chemotherapy (Premetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
    2010 to Present